Related Experiment Video
Updated: Jul 19, 2026
06:26
Novel and Innovative Hybrid Technique for Type A Aortic Dissection
Published on: March 28, 2025
Angiotensin converting enzyme inhibitors and aortic arch obstructive malformations
Kadivar Maliheh1, Kiani Abdorrazagh, Kocharian Armen
1Department of Neonatology, Tehran University of Medical Sciences, Children's Medical Center, Tehran, Iran.
Indian Journal of Medical Sciences
|September 29, 2006
Summary
Captopril can cause anuria in newborns with aortic arch defects. Close renal function monitoring is crucial when using angiotensin-converting enzyme inhibitors in these high-risk neonates.
Area of Science:
- Neonatal cardiology
- Pediatric nephrology
- Pharmacology
Background:
- Aortic arch obstructive malformations are critical congenital heart conditions.
- Angiotensin-converting enzyme (ACE) inhibitors are used in cardiovascular conditions.
- Neonates with congenital heart disease are vulnerable to hemodynamic changes.
Observation:
- Two neonates with aortic arch obstructive malformations were treated with captopril.
- Both infants developed anuria (inability to produce urine) post-initiation of captopril therapy.
Findings:
- Captopril, an ACE inhibitor, can significantly impair renal blood flow in neonates.
- The mechanism involves the reduction of angiotensin II and disruption of renal autoregulation.
- This can lead to acute kidney injury and anuria in susceptible infants.
Implications:
- ACE inhibitors should be used with extreme caution in neonates with aortic arch obstructive malformations.
- Continuous and close monitoring of renal function is essential during ACE inhibitor therapy in this population.
- Understanding these risks can help prevent severe adverse events and improve patient outcomes.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Aneurysm I: Introduction
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...